Two New Drugs for Chronic ITP
Romiplostim (Nplate - Amgen), a recombinant fusion protein injected subcutaneously, and eltrombopag (Promacta - GlaxoSmithKline), a non-peptide taken orally, have been approved by the FDA for treatment of chronic immune thrombocytopenic purpura (ITP) refractory to corticosteroids, immunoglobulins and/or splenectomy....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Two New Drugs for Chronic ITP
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1305
Article Code: 1305b
Date: February 9, 2009
Volume: 51
Pages: 10-11
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1305
Article Code: 1305b
Date: February 9, 2009
Volume: 51
Pages: 10-11
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)